

Rodolfo Chicas-Sett

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1498292/publications.pdf>

Version: 2024-02-01

37
papers

258
citations

1307543

7
h-index

940516

16
g-index

38
all docs

38
docs citations

38
times ranked

453
citing authors

#	ARTICLE	IF	CITATIONS
1	One-year efficacy and safety of naloxegol on symptoms and quality of life related to opioid-induced constipation in patients with cancer: KYONAL study. <i>BMJ Supportive and Palliative Care</i> , 2023, 13, e318-e326.	1.6	5
2	Single-fraction stereotactic ablative body radiation therapy for primary and metastatic lung tumor: A new paradigm?. <i>World Journal of Clinical Oncology</i> , 2022, 13, 101-115.	2.3	2
3	GOECP/SEOR radiotherapy guidelines for non-small-cell lung cancer. <i>World Journal of Clinical Oncology</i> , 2022, 13, 237-266.	2.3	6
4	Combination of SABR With Anti-PD-1 in Oligoprogressive Non-Small Cell Lung Cancer and Melanoma: Results of a Prospective Multicenter Observational Study. <i>International Journal of Radiation Oncology Biology Physics</i> , 2022, 114, 655-665.	0.8	15
5	Efficacy of naloxegol on symptoms and quality of life related to opioid-induced constipation in patients with cancer: a 3-month follow-up analysis. <i>BMJ Supportive and Palliative Care</i> , 2021, 11, 25-31.	1.6	12
6	Insights into the Use of Peripherally Acting μ -Opioid Receptor Antagonists (PAMORAs) in Oncologic Patients: from Scientific Evidence to Real Clinical Practice. <i>Current Treatment Options in Oncology</i> , 2021, 22, 26.	3.0	4
7	New challenges in the combination of radiotherapy and immunotherapy in non-small cell lung cancer. <i>World Journal of Clinical Oncology</i> , 2021, 12, 983-999.	2.3	2
8	Immunoradiotherapy as an Effective Therapeutic Strategy in Lung Cancer: From Palliative Care to Curative Intent. <i>Cancers</i> , 2020, 12, 2178.	3.7	25
9	1868P Efficacy and safety of naloxegol in patients with cancer with opioid-induced constipation with laxative-inadequate response: A long-term, real-world study. <i>Annals of Oncology</i> , 2020, 31, S1066.	1.2	1
10	SBRT Assisted By Real-Time Tracking And Duodenal Wall Sparing In Unresectable Locally Advanced Pancreatic Cancer. <i>International Journal of Radiation Oncology Biology Physics</i> , 2020, 108, e586.	0.8	0
11	Immuno-SABR Reboots the Immune Response in Patients with Metastatic NSCLC and Melanoma in Progression to Anti-PD-1 Therapy. <i>International Journal of Radiation Oncology Biology Physics</i> , 2020, 108, S73-S74.	0.8	2
12	Stereotactic ablative radiotherapy for oligometastatic breast cancer in elderly patients. <i>Translational Cancer Research</i> , 2020, 9, S197-S206.	1.0	0
13	PO-1272: Immunoradiotherapy induces a rechallenge of the immune response in elderly patients.. <i>Radiotherapy and Oncology</i> , 2020, 152, S669-S670.	0.6	0
14	Analysis of the efficacy of naloxegol in a real-world 12 weeks of follow-up study, in patients with cancer and opioid-induced constipation with laxative-inadequate response. <i>Annals of Oncology</i> , 2019, 30, v740.	1.2	1
15	EP-1443 Real-time tumor tracking in pancreatic SBRT by percutaneous US-guide implantation of transponders. <i>Radiotherapy and Oncology</i> , 2019, 133, S783-S784.	0.6	0
16	OC-0060 I-SABR induces local and abscopal responses in metastatic patients after failure to ICI treatment. <i>Radiotherapy and Oncology</i> , 2019, 133, S24.	0.6	3
17	Stereotactic Ablative Radiotherapy Combined with Immune Checkpoint Inhibitors Reboots the Immune Response Assisted by Immunotherapy in Metastatic Lung Cancer: A Systematic Review. <i>International Journal of Molecular Sciences</i> , 2019, 20, 2173.	4.1	68
18	Nanoparticles as a promising method to enhance the abscopal effect in the era of new targeted therapies. <i>Reports of Practical Oncology and Radiotherapy</i> , 2019, 24, 86-91.	0.6	16

#	ARTICLE	IF	CITATIONS
19	Interobserver variability in rectum contouring in high-dose-rate brachytherapy for prostate cancer: A multi-institutional prospective analysis. <i>Brachytherapy</i> , 2018, 17, 208-213.	0.5	6
20	Combining radiotherapy and ipilimumab induces clinically relevant radiation-induced abscopal effects in metastatic melanoma patients: A systematic review. <i>Clinical and Translational Radiation Oncology</i> , 2018, 9, 5-11.	1.7	76
21	High-dose-rate brachytherapy boost for prostate cancer: Analysis of dose-volume histogram parameters for predicting late rectal toxicity. <i>Brachytherapy</i> , 2017, 16, 511-517.	0.5	8
22	PO-0726: Dose escalation with HDR brachytherapy for intermediate- and high-risk prostate cancer. <i>Radiotherapy and Oncology</i> , 2017, 123, S380-S381.	0.6	0
23	EP-1538: VMAT craniospinal radiotherapy, planning strategy and results in twenty pediatric and adult patients. <i>Radiotherapy and Oncology</i> , 2017, 123, S826-S827.	0.6	0
24	Assessing the Relationship Between Dose-Volume Histogram Parameters and Late Rectal Toxicity in HDR Brachytherapy for Prostate Cancer. <i>Brachytherapy</i> , 2017, 16, S111.	0.5	0
25	An evaluation of the robustness of organ-at-risk recommendations made by GEC/ESTRO according to interobserver variability: a single-center experience. <i>Journal of Contemporary Brachytherapy</i> , 2016, 4, 349-355.	0.9	2
26	EP-1234: VMAT based lung ablative radiotherapy: primary lesions and metastases. <i>Radiotherapy and Oncology</i> , 2016, 119, S585.	0.6	0
27	EP-2008: Robustness of the OARs recommendations made by GEC-ESTRO according to inter-observer variability. <i>Radiotherapy and Oncology</i> , 2016, 119, S949.	0.6	0
28	Simple Templates To Be Used for Reproducible Positioning of Skin Applicators in Skin Brachytherapy. <i>Brachytherapy</i> , 2016, 15, S84-S85.	0.5	0
29	PV-0035: Electronic brachytherapy for basal cell carcinoma: two prospective pilot trials with different doses. <i>Radiotherapy and Oncology</i> , 2016, 119, S14.	0.6	0
30	An Evaluation of the Robustness of the Organ-at-Risk Recommendations Made by GEC/ESTRO According to Inter- and Intra- Observer Variability: A Single Center Experience. <i>Brachytherapy</i> , 2016, 15, S188.	0.5	0
31	A case report of recurrent adult-onset xanthogranuloma: is the radiotherapy a treatment option?. <i>International Cancer Conference Journal</i> , 2016, 5, 77-81.	0.5	2
32	Intravascular Biphasic Synovial Sarcoma: The Beneficial Role of Adjuvant Treatment Approach in the Pre-metastatic Stage. <i>Cureus</i> , 2016, 8, e572.	0.5	2
33	Early Toxicity Outcomes: A Single 15-Cy Fraction High-Dose-Rate Brachytherapy as Pretreatment External Beam Radiation Therapy Boost in Prostate Cancer. <i>International Journal of Radiation Oncology Biology Physics</i> , 2015, 93, E208.	0.8	0
34	Early toxicity outcomes: A single 15Gy fraction HDR brachytherapy as pre-treatment EBRT boost in prostate cancer. <i>Radiotherapy and Oncology</i> , 2015, 115, V.	0.6	0
35	PO-0723: Early toxicity outcomes: A single 15Gy fraction HDR brachytherapy as pre-treatment EBRT boost in prostate cancer. <i>Radiotherapy and Oncology</i> , 2015, 115, S357.	0.6	0
36	EP-1256: Salvage iodine-125 brachytherapy for local prostate cancer recurrence after radiotherapy. <i>Radiotherapy and Oncology</i> , 2015, 115, S679.	0.6	0

#	ARTICLE	IF	CITATIONS
37	EP-1897: Clinical outcomes and toxicity in MRI based cervical brachytherapy. Radiotherapy and Oncology, 2014, 111, S321.	0.6	0